The “Monthly Roundup” is a monthly newsletter dedicated to sharing the latest news from the Duke Global Health Innovation Center and Innovations in Healthcare. View the September 2024 newsletter. Subscribe to the monthly newsletter.
Welcome to the second installment of the Innovations in Healthcare Global Health Innovation Grantees blog series. Access the first blog here. History of the Global Health Innovation Grants Program Since 2016, The Pfizer Foundation’s Global Health Innovation Grants (GHIG) program has supported community-based initiatives that aim to improve quality of care and strengthen health systems in lower income countries. Innovations in Healthcare supports GHIG grantees by facilitating connections, hosting program-specific workshops and peer convenings at the Annual Forum while also conducting regular program monitoring to provide portfolio and individual results to the Pfizer Foundation. Now in its eighth year (GHIG8), 20 new recipients have each received a USD $100,000 one-year grant to drive innovative solutions that help address vaccine-preventable illness in their communities. [caption id="attachment_5800" align="aligncenter" width="596"] GHIG8 geographic scope. This year’s grantees…
The “Monthly Roundup” is a monthly newsletter dedicated to sharing the latest news from the Duke Global Health Innovation Center and Innovations in Healthcare. View the August 2024 newsletter. Subscribe to the monthly newsletter.
The 2024-25 Global Health Innovation Grantees Blog Series 1 of 4, via Innovations in Healthcare History of the Global Health Innovation Grants Program Since 2016, The Pfizer Foundation’s Global Health Innovation Grants (GHIG) program has supported community-based initiatives that aim to improve quality of care and strengthen health systems in lower income countries. Innovations in Healthcare supports GHIG grantees by facilitating connections, hosting program-specific workshops and peer convenings at the Annual Forum while also conducting regular program monitoring to provide portfolio and individual results to the Pfizer Foundation. Now in its eighth year (GHIG8), 20 new recipients have each received a USD $100,000 one-year grant to drive innovative solutions that help address vaccine-preventable illness in their communities. [caption id="attachment_5800" align="aligncenter" width="596"] GHIG8 geographic scope. This year’s grantees address a range of infectious diseases…
The “Monthly Roundup” is a monthly newsletter dedicated to sharing the latest news from the Duke Global Health Innovation Center and Innovations in Healthcare. View the July 2024 newsletter. Subscribe to the monthly newsletter.
This newsletter aims to provide a central hub for information, milestones, and updates regarding the COVID Treatment QuickStart Consortium. The COVID Treatment QuickStart Consortium partners with governments to rapidly introduce and scale access to COVID-19 oral antiviral therapies in vulnerable and high-risk populations presenting with mild to moderate symptoms within five days of symptom onset through a public health test-and-treat model. QuickStart’s top priorities are: Ensuring treatments are accessible in all parts of the world; Preparing for potential future COVID-19 surges; and Building primary healthcare capacity for test-and-treat beyond COVID-19. View the July 2024 QuickStart newsletter. Subscribe to the QuickStart newsletter.
Market access to COVID-19 oral therapeutics in low- and middle-income (LMIC) countries was delayed. It took nearly fifteen months from the US FDA emergency use listing for nirmatrelvir/ritonavir to be delivered to the first LMIC countries by global buyers, long after the major COVID-19 waves had passed. Vaccines played a major role in managing the pandemic; next time the first line of defense may be therapeutics, reinforcing the need to identify key insights and develop recommendations that will hasten the process in future global emergencies. The QuickStart Consortium undertook a rapid policy analysis to understand global and national level factors that delayed market access to oral antivirals. The analysis established that significant but solvable challenges slowed down the time taken to get the oral antivirals to people when they needed…
The “Monthly Roundup” is a monthly newsletter dedicated to sharing the latest news from the Duke Global Health Innovation Center and Innovations in Healthcare. View the June 2024 newsletter. Subscribe to the monthly newsletter.
Antimicrobial resistance (AMR) is a significant global public health menace. When antimicrobials are ineffective against previously treatable infections, it undermines the ability of health systems around the world to treat even minor infections, resulting in more expensive treatments, and excess mortality and morbidity when infections become untreatable. A recent study on the burden of AMR estimates nearly 5 million deaths associated with bacterial AMR in 2019, with 1.3 million deaths attributable to bacterial AMR 1, suggesting that AMR is at least as large as HIV and malaria. Of all the regions, Sub-Saharan Africa has the highest mortality rate from bacterial AMR at 27.3 deaths per 100,000.1 This high burden is exacerbated by a shortage of trained professionals and limited microbiology laboratory capabilities. In fact, only 1.3% of the 50,000 medical laboratories in…
via Innovations in Healthcare. Antimicrobial resistance (AMR) is a significant global public health menace. The highest mortality rates are seen in Sub-Saharan Africa, where there is a significant shortage of trained professionals and microbiology laboratories for antimicrobial susceptibility testing. To address this, Pfizer Inc., Wellcome Trust, and the Ministries of Health in Ghana, Kenya, Malawi, and Uganda initiated the Surveillance Partnership to Improve Data for Action on AMR (SPIDAAR), a pilot public-private partnership. SPIDAAR aimed to enhance AMR surveillance by training staff in eight hospitals across four countries to conduct diagnostics on 100 isolates per site for five leading pathogens. The isolates were sent to the National Institute for Communicable Diseases (NICD) in South Africa for confirmation, facilitating trend analysis and feedback on culture accuracy. In May 2021, Pfizer engaged Innovations…
